Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging

Complete title: Personalized Radiation Therapy through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)

Research Study Number 9599
 
Principal Investigator Jing Zeng
 
Phase II

Research Study Description

This phase II trial studies how well positron emission tomography (PET)/computed tomography (CT) and single positron emission computed tomography (SPECT)/CT imaging works in improving radiation therapy treatment in patients with stage IIB-IIIB non-small cell lung cancer. PET/CT imaging mid-way through treatment may be able to accurately show how well radiation therapy and chemotherapy are working. SPECT/CT imaging may be able to tell which parts of the lung tissue are healthier than others. Based on the result of the imaging, treatment adjustments may be made to the radiation therapy to improve survival and decrease toxicity.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Both

- Pathologically proven (either histologic or cytologic) diagnosis of stage IIB-IIIB non-small cell lung cancer (NSCLC); according to American Joint Committee on Cancer (AJCC) staging, 7th edition

-- * Staging workup must include: brain imaging (CT head or magnetic resonance imaging [MRI] brain) and PET/CT

-- * Pleural effusions must have cytology to rule out malignant involvement unless too small to undergo thoracentesis per radiology

- Patients must be considered unresectable or inoperable

- Patient must not have received prior radiation for this lung cancer

- Patients must be having concurrent chemotherapy

- Nodal recurrences can be treated on this protocol but prior curative surgery for lung cancer must have been at least 6 months prior to the nodal recurrence

- Patients must have measurable or evaluable disease that is FDG avid with standardized uptake value (SUV) > 3 on PET/CT

- Zubrod performance status 0-1

- PFTs including forced expiratory volume in 1 second (FEV1) within 26 weeks prior to registration; for FEV1, the best value obtained pre- or post-bronchodilator must be >= 0.8 liters/second or >= 50% predicted

- Blood cell count (CBC)/differential obtained within 8 weeks prior to registration on study

- Absolute neutrophil count (ANC) >= 1,800 cells/mm^3

- Platelets >= 100,000 cells/mm^3

- Hemoglobin >= 10.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin (Hgb) >= 10.0 g/dl is acceptable)

- Serum creatinine within normal institutional limits or creatinine clearance >= 40 ml/min

- Bilirubin must be within or below normal institutional limits

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x the institutional upper limit of normal (IULN)

- Patient must sign study specific informed consent prior to study entry

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- > 10% unintentional weight loss within the past month

- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; non-invasive conditions such as carcinoma in situ of the breast, oral cavity, or cervix are all permissible

- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields

- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception

Other exclusion criteria may apply.

Research Study Number 9599
 
Contact Jing Zeng
 
Telephone 206/598-4100
 
E-mail
 

Keywords: Lung Cancer; Solid Tumors; Lung Carcinoma, Non-Small-Cell (NSCLC); Carcinoma, Bronchogenic

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials